Biopharmaceutical company Aridis Pharmaceuticals, Inc. (ARDS) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.
from RTT - Biotech https://ift.tt/2Xdjt6G
via IFTTT
No comments:
Post a Comment